What is spasentan (sparsentan)? What diseases is it used to treat?

Sparsentan (also known as Sparsentan in Chinese) is a new type of oral small molecule drug. It is mainly used as a dual-targeting drug of endothelin receptor A antagonist and angiotensin II type II receptor blocker. This mechanism allows it to play an important role in inhibiting vasoconstriction, improving renal blood flow, and reducing proteinuria. It is especially suitable for patients with kidney disease and has strong clinical potential.

Currently, sparsentane is mainly used to treat two rare but serious kidney diseases: one is focal segmental glomerulosclerosis (FSGS), and the other isIgA nephropathy (IgAN). Both diseases are chronic kidney diseases. Patients often suffer from proteinuria, decreased renal function and other symptoms. If not intervened in time, they may develop into end-stage renal disease. Sparsentane has shown significant proteinuria-reducing effects in clinical studies and is considered a promising treatment for delaying the deterioration of renal function.

In terms of therapeutic mechanism, sparsentane is unique in its dual receptor antagonism. It blocks endothelinA receptors in the endothelin pathway that cause vasoconstriction and inflammation, and blocks angiotensinII type receptors, thereby reducing glomerular pressure, lowering inflammation levels and reducing protein leakage. This mechanism not only helps control the disease, but may also play a positive role in long-term renal function protection, providing patients with new treatment hope.

Although sparsentan has not yet been officially launched in China, there are already use cases in Europe and the United States and other places, and it has been granted orphan drug status by regulatory agencies in some countries. For Chinese patients, if they want to obtain the drug, they may need to obtain it through overseas medical channels. During the medication process, patients should strictly follow the doctor's instructions and pay attention to blood pressure, electrolytes, liver function and other indicators to ensure medication safety. As global attention to kidney disease increases, sparsentin is expected to be approved and widely used in more countries and regions in the future.

Reference materials:https://www.sparsentan.com/